BOSTON, Jan. 08, 2026 -- Aktis Oncology, Inc. (“Aktis”), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed...
Afferent Pharmaceuticals named one of "The Hottest Startups of 2015" by Forbes
News | 01. 05. 2016
Afferent Pharmaceuticals
Afferent Pharmaceuticals named one of "The Hottest Startups of 2015" by Forbes.
